Tanious Mariah Kincaid, Beutler Sascha S, Kaye Alan D, Urman Richard D
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Department of Anesthesiology and Pain Medicine, Louisiana State University School of Medicine, LSU Health Science Center, 1542 Tulane Avenue, Room 659, New Orleans, LA 70112, USA.
Anesthesiol Clin. 2017 Jun;35(2):e95-e113. doi: 10.1016/j.anclin.2017.01.017. Epub 2017 Apr 14.
Since the public demonstration of ether as a novel, viable anesthetic for surgery in 1846, the field of anesthesia has continually sought the ideal anesthetic-rapid onset, potent sedation-hypnosis with a high therapeutic ratio of toxic dose to minimally effective dose, predictable clearance to inactive metabolites, and minimal side effects. This article aims to review current progress of novel induction agent development and provide an update on the most promising drugs poised to enter clinical practice. In addition, the authors describe trends in novel agent development, implications for health care costs, and implications for perioperative care.
自1846年乙醚作为一种新型、可行的手术麻醉剂公开演示以来，麻醉领域一直在不断寻找理想的麻醉剂——起效迅速、强效镇静催眠，毒剂量与最小有效剂量的治疗比值高，可预测地清除为无活性代谢产物，且副作用最小。本文旨在综述新型诱导剂开发的当前进展，并提供有望进入临床实践的最有前景药物的最新情况。此外，作者还描述了新型药物开发的趋势、对医疗保健成本的影响以及对围手术期护理的影响。
